{
 "query": "ubrogepant",
 "ingredient": "ubrogepant",
 "slug": "ubrogepant",
 "rxcui": "2268216",
 "brands": [
  "Ubrelvy"
 ],
 "names": [
  "ubrogepant"
 ],
 "classes": [
  {
   "id": "N02CD",
   "name": "Calcitonin gene-related peptide (CGRP) antagonists"
  }
 ],
 "alternatives": [
  "atogepant",
  "eptinezumab",
  "erenumab",
  "fremanezumab",
  "galcanezumab",
  "rimegepant",
  "zavegepant"
 ],
 "label": {},
 "faers": {
  "total": 6026,
  "serious": 2118,
  "death": 100,
  "hospitalization": 644,
  "primary_suspect": 6021,
  "top_reactions": [
   [
    "Drug Ineffective",
    1039
   ],
   [
    "Migraine",
    878
   ],
   [
    "Headache",
    541
   ],
   [
    "Nausea",
    528
   ],
   [
    "Fatigue",
    369
   ],
   [
    "Off Label Use",
    287
   ],
   [
    "Dizziness",
    274
   ],
   [
    "Pain",
    264
   ],
   [
    "Product Dose Omission Issue",
    223
   ],
   [
    "Vomiting",
    215
   ],
   [
    "Pruritus",
    172
   ],
   [
    "Injection Site Pain",
    167
   ],
   [
    "Diarrhoea",
    166
   ],
   [
    "Somnolence",
    156
   ],
   [
    "Covid-19",
    155
   ]
  ],
  "by_year": {
   "2019": 17,
   "2020": 451,
   "2021": 650,
   "2022": 1124,
   "2023": 944,
   "2024": 1049,
   "2025": 1094,
   "2026": 681
  },
  "by_year_primary": {
   "2019": 17,
   "2020": 451,
   "2021": 650,
   "2022": 1124,
   "2023": 944,
   "2024": 1048,
   "2025": 1091,
   "2026": 680
  }
 },
 "faers_base": {
  "total": 20692304,
  "serious_share": 0.5742697381596559,
  "death_share": 0.09102355155810585
 },
 "recalls": [],
 "recall_total": 0,
 "drugsfda": {
  "applications": 4,
  "nda": 1,
  "anda": 0,
  "first_approval": "20191223",
  "rems": false,
  "rems_last": "",
  "labeling_supplements": 4,
  "labeling_recent": 4,
  "sponsors": [
   "ABBVIE",
   "AUROBINDO PHARMA LIMITED",
   "MSN LABORATORIES PRIVATE LIMITED",
   "ZYDUS PHARMACEUTICALS (USA) INC."
  ],
  "unapproved": false,
  "first_approval_fmt": "12/23/2019"
 },
 "trials": {
  "total": 24,
  "completed": 15,
  "terminated": 1,
  "with_results": 8,
  "industry": 21,
  "phase3": 7,
  "results_share": 0.5333333333333333,
  "terminated_share": 0.041666666666666664
 },
 "pubmed": {
  "rct": 22,
  "meta": 11,
  "recent_rct": 11,
  "cochrane": []
 },
 "payments": {
  "year": "2024",
  "usd": 6189625.77,
  "records": 183906,
  "by_name": [
   [
    "Ubrelvy",
    6189625.77
   ]
  ],
  "names_checked": [
   "ubrogepant",
   "Ubrelvy"
  ],
  "source": "bulk-index"
 },
 "partd": {
  "year": "2024",
  "claims": 328213,
  "beneficiaries": 83437,
  "spend": 429537897.96,
  "by_brand": [
   {
    "brand": "Ubrelvy",
    "claims": 328213,
    "per_claim": 1308.7168941,
    "is_generic": false
   }
  ],
  "per_claim": 1308.7168940901183
 },
 "mdl": [],
 "dsc": [],
 "settlements": [],
 "prescrire": null,
 "eml": {
  "listed": false,
  "status": "",
  "name": "",
  "matched": null,
  "stewardship": []
 },
 "exposure": {
  "years": [
   "2024",
   "2025",
   "2026"
  ],
  "reports_recent": 2819,
  "fills": 328213,
  "per_million": 8588.93462477111,
  "ratio": 3.101874497005096,
  "median": 2768.949753790441
 },
 "scores": {
  "safety": {
   "score": 90,
   "letter": "A",
   "why": [
    "8,589 FDA reports naming it as the suspect drug per million Medicare fills, 3.1x the median drug on this site (-10)",
    "Death share in reports is near or below the FAERS average (0.2x)"
   ],
   "weight": 0.35
  },
  "evidence": {
   "score": 40,
   "letter": "F",
   "why": [
    "22 randomized trials and 11 systematic reviews/meta-analyses indexed in PubMed",
    "No Cochrane review found (-5)",
    "'Drug ineffective' is the single most-reported item about this drug in FAERS (-5)"
   ],
   "weight": 0.25
  },
  "regulatory": {
   "score": 96,
   "letter": "A",
   "why": [
    "No recalls on record since 2016",
    "4 label changes approved since 2021 (-4)"
   ],
   "weight": 0.15
  },
  "conflict": {
   "score": 70,
   "letter": "C",
   "why": [
    "Pharma paid doctors $6,189,626 tied to this drug last year (-30)",
    "Not named in any pending federal MDL"
   ],
   "weight": 0.15
  },
  "options": {
   "score": 70,
   "letter": "C",
   "why": [
    "No generic version approved: brand-only pricing (-30)",
    "7 same-class alternatives exist"
   ],
   "weight": 0.1
  }
 },
 "total": 73,
 "grade": "C",
 "questions": [
  "The most-reported problems in FDA's adverse event data are migraine, headache, nausea. How would we recognize and handle those?",
  "Off-label use is among the most-reported items for this drug. Is my use on-label, and if not, what evidence supports it?",
  "Why this one over atogepant, eptinezumab, erenumab? What would make you pick one of those instead?",
  "There is no generic. Is there an older generic in the same class that works as well for my situation?",
  "The manufacturer pays physicians heavily to promote this drug. Have you received anything from them?",
  "What result are we expecting, by when, and what is the plan if it does not happen?",
  "If 100 people like me took this drug, how many would actually get better because of it, and how many would be harmed by it? (Doctors call these the number needed to treat and the number needed to harm.)"
 ]
}